Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
23. Dezember 2024 04:00 ET
|
Alvotech
Addition is part of the annual reconstitution of the Nasdaq Biotech Index (NBI)Inclusion criteria include minimum market capitalization and daily trading volumes REYKJAVIK, Iceland, Dec. 23, 2024 ...
Hlutabréf Alvotech tekin inn í Líftæknivístölu Nasdaq
23. Dezember 2024 04:00 ET
|
Alvotech
Alvotech verður hluti af NBI vísitölunni við opnun markaða í Bandaríkjunum 23. desember 2024 Alvotech (NASDAQ: ALVO) tilkynnti í dag að hlutabréf félagsins hafi verið tekin inn í Líftæknivísitölu...
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
23. Dezember 2024 04:00 ET
|
Alvotech
Addition is part of the annual reconstitution of the Nasdaq Biotech Index (NBI)Inclusion criteria include minimum market capitalization and daily trading volumes Alvotech (NASDAQ: ALVO), a global...
CBIH Unveils the Future of Wellness with Revolutionary Anti-Aging Chip
25. November 2024 08:00 ET
|
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
our Research and Development team is redefining the possibilities of cannabinoid-based biotechnologies and at the heart of these innovations lies the Rejuv
CBIH Strengthens Clinical Research Team in Preparation for Launch of Next-Generation Cannabinoid Solutions
18. November 2024 08:00 ET
|
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) continues to invest in top-tier talent as it prepares to launch its specialized pharmaceutical a
Alvotech Reports Financial Results for the First Nine Months of 2024
13. November 2024 16:05 ET
|
Alvotech
Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first nine...
Alvotech birtir fjárhagsuppgjör fyrir fyrstu níu mánuði ársins 2024
13. November 2024 16:05 ET
|
Alvotech
Heildartekjur á fyrstu níu mánuðum ársins jukust um 300 milljónir dala frá sama tímabili árið 2023, í 339 milljónir dala, þar af voru tekjur 103 milljónir dala á þriðja ársfjórðungi Tekjur af vörusölu...
Alvotech Reports Financial Results for the First Nine Months of 2024
13. November 2024 16:05 ET
|
Alvotech
Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first nine...
Alvotech fundar með fjárfestum á heilbrigðisráðstefnum Citi og Evercore fjárfestingabankanna dagana 4. og 5. desember 2024
07. November 2024 08:00 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tekur þátt árlegum í heilbrigðisráðstefnum alþjóðlegu fjárfestingabankanna Citi og Evercore, dagana 4.-5. desember n.k. Auk þess að funda með fjárfestum munu stjórnendur...
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
07. November 2024 08:00 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Citi’s 2024...